Open AccessSerum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy
Author(s) -
Bolayirli M.,
Papila C.,
Korkmaz G. G.,
Papila B.,
Aydoğan F.,
Karataş A.,
Uzun H.
Publication year - 2013
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.21587
Subject(s) - medicine , breast cancer , colorectal cancer , chemotherapy , oncology , cancer
Background The aim of this study was to evaluate the changing of TK 1 (where TK is thymidine kinase) activity before and after adjuvant chemotherapy in patients with breast and colorectal cancer. Methods The study included 16 breast cancer, 25 colorectal cancer, and 38 healthy volunteers as the control group. Blood samples were taken twice from each patient; first at the beginning of the chemotherapy and second after six cycles of chemotherapy. TK 1 activity was measured enzyme immunoassay method. Results The mean TK 1 activity in the breast and colorectal cancer was significantly higher than the controls. TK 1 activity in the colorectal cancer was higher than the breast cancer but this difference was not significant. TK 1 activity after six doses of chemotherapy was lower than baseline TK 1 activity before the start of chemotherapy in breast and colorectal cancer. TK 1 activity was positively correlated with CA15–3, before and after chemotherapy in patients with breast cancer. TK 1 activity in the colorectal cancer was also positively correlated with CA19–9, before and after chemotherapy. The values for the cutoff point, sensitivity, specificity, and the area under curve were determined for TK 1 as >44.36 Du/L, 68.29%, 100% and 0.819, respectively in all subjects. Conclusion Our results showed that serum TK 1 activity in patients with breast and colorectal cancer was significantly higher than that of the healthy controls. Moreover, after the completion of chemotherapy the values were lower than baseline. Pretreatment TK 1 activity should be considered as a useful marker for assessment tumor cell proliferation in breast and colorectal cancer. Further work is needed to understand TK 1 activity better in large populations of patients with solid tumor.